What question did this study set out to answer?

The study investigates the effectiveness and safety of combining Zanubrutinib with R-CHOP in patients with MCD-type DLBCL.

December 8, 2025BloodOpen Access

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

View Full Paper

Ask AI

Bookmark

Authors

YLYing LuNingbo University LSLihong ShouHuzhou Central Hospital JJJie JinTianjin University

Discussion

Member takes

Implication

Clinical trial shows improved progression-free survival in DLBCL patients with MYD88 and CD79B mutations, indicating Zanubrutinib may enhance treatment outcomes.

Key Points

The study investigates the effectiveness and safety of combining Zanubrutinib with R-CHOP in patients with MCD-type DLBCL.
Conducted a clinical trial with patients treated with Zanubrutinib plus R-CHOP.
Enrolled untreated DLBCL patients with both MYD88L265P and CD79B mutations.
Evaluated primary endpoint of progression-free survival (PFS) and secondary endpoints including overall response rate (ORR).
92.5% overall response rate (ORR) with 87.5% achieving complete remission (CR).
Estimated 2-year PFS rate was 95% and OS rate was 97.4%.
Adverse events included neutropenia (58.1%), with 37.2% experiencing grade 3 or 4 events.

Cite This Study

Lu et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd7c https://doi.org/10.1182/blood-2025-1907

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial shows improved progression-free survival in DLBCL patients with MYD88 and CD79B mutations, indicating Zanubrutinib may enhance treatment outcomes.

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

Discussion

Member takes

Implication

Key Points

Cite This Study

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider